---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-015695"
form_type: "8-K"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T21:48:45.262528+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Avalo Q1 net loss narrows to $9.955M; cash $16.7M; AVTX-002 topline due Q2 2023

## Summary
- Net loss $9.955M ($0.85/share) vs $22.051M ($2.35) in Q1 2022; revenue $475K down from $1.173M.
- Cash and equivalents $16.687M at March 31, 2023, up $3.515M from Dec 31, 2022 due to $13.7M equity financing.
- Phase 2 PEAK trial of AVTX-002 in non-eosinophilic asthma completed enrollment (91 patients); topline data expected Q2 2023.
- Operating expenses cut to $9.267M from $22.026M, driven by cost savings initiatives implemented in Q1 2022.
- AVTX-008 lead molecule identified; IND submission planned for 2024. AVTX-803 LADDER trial timing under evaluation.

## SEC filing metadata
- accession: 0001628280-23-015695
- form_type: 8-K
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000162828023015695/0001628280-23-015695-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000162828023015695/avtx-20230504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-015695
- JSON: https://secwatch.observer/filing/0001628280-23-015695.json
- Plain text: https://secwatch.observer/filing/0001628280-23-015695.txt

## Key facts
- Earnings Releases
  Avalo Therapeutics, Inc. reported quarter ended March 31, 2023 results: revenue $475, net income $(9,955), EPS $(0.85).
  - Period: quarter ended March 31, 2023
  - Revenue: $475
  - Net income: $(9,955)
  - EPS: $(0.85)
  - Result: reported results
  source text: Product revenue, net $ 475 $ 1,173 Total revenues, net 475 1,173 Operating expenses: Cost of product sales 551 720 Research and development 6,008 9,584 Selling, general and administrative 2,708 11,684 Amortization expense — 38 Total operating expenses 9,267 22,026 (8,792) (20,853) Other expense: Interest expense, net (949) (1,169) Change in fair value of derivative liability (180) — Other expense, net (26) (20) Total other expense, net (1,155) (1,189) Loss before taxes (9,947) (22,042) Income tax expense 8 9 Net loss and comprehensive loss $ (9,955) $ (22,051) Net loss per share of common stock, basic and diluted 1 $ (0.85) $ (2.35)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534120/000162828023015695/0001628280-23-015695-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.